Prime Medicine Inc (PRME) Hedge Fund Ownership (Q1 2026)

Q: Is it too late to buy Prime Medicine Inc (PRME) following the 2026 Q2 hedge fund 13F filings?

As of today, PRME has moved +0.0% since the 2026 Q2 13F filing date (August 14, 2026), compared to +0.0% for the XLV sector ETF — an outperformance of +0.0%. Since the quarter end (June 30, 2026), PRME gained -16.3% vs +5.5% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Prime Medicine Inc (PRME)

187 + Investors. Track Smart Money conviction in PRME. See who's accumulating, reducing, or initiating positions.

Smart Money Signals — PRME

Based on 189 hedge funds · latest filing: 2026 Q1 · updated quarterly

📈

Buying streak — 3 quarters in a row

last 6Q

For 3 consecutive quarters, more hedge funds added PRME than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

🏔️

At the ownership peak (100% of max)

100% of all-time peak

189 hedge funds hold PRME right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.

🚀

Fast accumulation — +55% more funds vs a year ago

fund count last 6Q

+67 new funds entered over the past year (+55% YoY). That's a rapid rush of institutional money. Fast accumulation often signals a major thesis — but it also means the stock could fall quickly if that thesis breaks.

🟡

Slight buying edge — 58% buying

113 buying81 selling

Last quarter: 113 funds bought or added vs 81 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.

⚠️

Fewer new buyers each quarter (-9 vs last Q)

new funds entering per quarter

Funds opening this position for the first time: 28 → 50 → 48 → 39. Each quarter fewer new institutions are entering. This usually means most funds that wanted in are already in — the stock is well-known but the pool of potential new buyers is shrinking.

📌

Mixed — 32% long-term, 40% new

■ 32% conviction (2yr+) ■ 28% medium ■ 40% new

Of the 189 current holders: 61 (32%) held >2 years, 53 held 1–2 years, and 75 entered in the last year. A mixed base — the stock has long-term believers but also recent buyers who haven't been tested by a downturn yet.

📈

Growing discovery — still being found

22 → 28 → 50 → 48 → 39 new funds/Q

New funds entering each quarter: 28 → 50 → 48 → 39. A growing number of institutions are discovering PRME each quarter. The narrative is still spreading — leaving room for ongoing capital accumulation.

📊

Mixed cohorts — 37% veterans, 45% new entrants

■ 37% veterans ■ 18% 1-2yr ■ 45% new

Of 194 current holders: 72 (37%) held 2+ years, 34 held 1–2 years, 88 (45%) entered in the past year. Balanced distribution — some institutional memory, some recent momentum buyers.

✅

Strong quality — 38% AUM from major funds

38% from top-100 AUM funds

43 of 188 holders rank in the top 100 by AUM, accounting for 38% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.

4.7

out of 10

Moderate Exit Risk

Exit risk score 4.7/10 — some crowding factors present, but no critical concentration. Watch ownership trend over the next 1–2 quarters for direction.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Metric	All 13F Filers (2026 Q1)	Prior (2025 Q4)	Change
Funds Holding	187	181	3.31%
13F Shares	99M	93M	5.63%
Total Value	$321M	$324M	-0.92%
New Positions	37	47	-10
Increased Positions	73	62	+11
Closed Positions	31	28	+3
Reduced Positions	48	42	+6
Total Calls	3	5	-40.0%
Total Puts	3	3	-
PUT/CALL Ratio	1.0	0.6	Neutral

Metric

All 13F Filers (2026 Q1)

Prior (2025 Q4)

Change

Funds Holding

187

181

3.31%

13F Shares

99M

93M

5.63%

Total Value

$321M

$324M

-0.92%

New Positions

-10

Increased Positions

+11

Closed Positions

Reduced Positions

Total Calls

-40.0%

Total Puts

PUT/CALL Ratio

1.0

0.6

Neutral

Institutional Holders (2026 Q2)

187 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in PRME. Verified SEC 13F-HR filings.

QUARTER:

2026 Q2 filings are still coming in. Only funds that have filed so far are shown — top holders may not have reported yet. Full 13F data typically settles by ~50 days after quarter-end.

FILTER:All New Added To Reduced No Change | Overweight >5%

Top 25 PRME holders by conviction (% of portfolio weight) — 2026 Q1 · Source: SEC Form 13F
#	Investor	% of Portfolio	Shares	Mkt Value
1	Alessandra Capital Management, LLC	1.74%	666,603	$2.5M
2	Chelsea Counsel Co	0.70%	449,060	$1.7M
3	Casdin Capital, LLC	0.58%	3,167,175	$11.7M
4	Green Alpha Advisors, LLC	0.46%	185,023	$683K
5	Redmile Group, LLC	0.34%	1,389,632	$5.1M
6	ADAR1 Capital Management, LLC	0.34%	1,997,552	$7.4M
7	ARK Investment Management LLC	0.20%	8,348,746	$30.8M
8	Amova Asset Management Americas, Inc.	0.11%	2,407,018	$8.9M
9	Virtus Investment Advisers, LLC	0.10%	117,909	$435K
10	IvyRock Asset Management (HK) Ltd	0.09%	41,800	$154K
11	Palumbo Wealth Management LLC	0.08%	103,801	$383K
12	Alphabet Inc.	0.06%	16,562,498	$61.1M
13	Milestone Asset Management, LLC	0.06%	100,035	$369K
14	IQ EQ FUND MANAGEMENT (IRELAND) Ltd	0.05%	225,799	$833K
15	Keystone Financial Group	0.04%	166,510	$614K
16	Woodline Partners LP	0.03%	3,003,904	$11.1M
17	Thompson Davis & CO., INC.	0.03%	14,590	$54K
18	Shelton Wealth Management, LLC	0.03%	19,105	$70K
19	Moore Capital Management, LP	0.03%	500,000	$1.8M
20	Balyasny Asset Management L.P.	0.02%	3,969,082	$14.6M
21	Blue Bell Private Wealth Management, LLC	0.01%	25,830	$95K
22	Abacus Planning Group, Inc.	0.01%	25,188	$93K
23	XTX Topco Ltd	0.01%	215,708	$796K
24	Profund Advisors LLC	0.01%	72,624	$268K
25	China Universal Asset Management Co., Ltd.	0.01%	28,745	$106K

Investor	Ownership History	% of Portfolio	Prev %	Rank	Conviction	Avg Buy Price	13F Score™ 3Y / 7Y	Sell Timing	Shares	Mkt Value	Change	Change %	Source	Quarter	Filed

Frequently Asked Questions — Prime Medicine Inc (PRME)

What does the Smart Money Trend signal show for PRME?

Buying streak — 3 quarters in a row: For 3 consecutive quarters, more hedge funds added PRME than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for PRME?

Slight buying edge — 58% buying: Last quarter: 113 funds bought or added vs 81 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.

What is the fund quality score for PRME holders?

Strong quality — 38% AUM from major funds: 43 of 188 holders rank in the top 100 by AUM, accounting for 38% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.

How long have hedge funds held PRME?

Mixed — 32% long-term, 40% new: Of the 189 current holders: 61 (32%) held >2 years, 53 held 1–2 years, and 75 entered in the last year. A mixed base — the stock has long-term believers but also recent buyers who haven't been tested by a downturn yet.

Is it too late to buy Prime Medicine Inc (PRME) following the 2026 Q2 hedge fund 13F filings?

As of today, PRME has moved +0.0% since the 2026 Q2 13F filing date (August 14, 2026), compared to +0.0% for the XLV sector ETF — an outperformance of +0.0%. Since the quarter end (June 30, 2026), PRME has gained -16.3% vs +5.5% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Market Cap	--
Enterprise Value	--
Trailing P/E	--
Forward P/E	--
PEG Ratio (5yr expected)	--
Price/Sales (ttm)	--
Price/Book (mrq)	--
Enterprise Value/Revenue	--
Enterprise Value/EBITDA	--
Beta (5Y Monthly)	--
Short Ratio (Days to Cover)	--
Short % of Float	--

Profit Margin	--
Return on Assets (ttm)	--
Return on Equity (ttm)	--

Revenue (ttm)	--
Net Income Avi to Common (ttm)	--
Diluted EPS (ttm)	--
Total Cash (mrq)	--
Total Debt/Equity (mrq)	--
Levered Free Cash Flow (ttm)	--

Prime Medicine Inc (PRME)

Smart Money Signals — PRME

Buying streak — 3 quarters in a row

At the ownership peak (100% of max)

Fast accumulation — +55% more funds vs a year ago

Slight buying edge — 58% buying

Fewer new buyers each quarter (-9 vs last Q)

Mixed — 32% long-term, 40% new

Growing discovery — still being found

Mixed cohorts — 37% veterans, 45% new entrants

Strong quality — 38% AUM from major funds

Institutional Sentiment Summary — PRME

Hedge Fund Ownership: PRME

Market Analysis: PRME

Analyst Price Targets

Analyst Recommendations

Stock Performance

Company Profile: PRME

Is It Too Late to Buy Prime Medicine Inc (PRME) Based on Hedge Fund 13F Filings?

Hedge Fund Positioning: PRME

Statistics: PRME

Valuation Measures Data as of: --

Financial Highlights

Institutional Holders (2026 Q2)

Frequently Asked Questions — Prime Medicine Inc (PRME)

Welcome to 13Foresight!